Andrew Lazerow represents domestic and international clients in some of their most important complex commercial litigation, including antitrust class actions and competitor disputes, securities fraud class actions, and complex commercial disputes. Mr. Lazerow regularly represents leading pharmaceutical clients in antitrust class actions arising from settlements of Hatch-Waxman ANDA patent litigation.
19
What occurred and why does it matter? President Trump on October 24 signed the SUPPORT for Patients and Communities Act (H.R. 6), which together with the Patient Right to Know Drug Prices Act (S. 2554), signed October 10, expands the scope of pharmaceutical product-related agreements subject (...)
25
The Federal Trade Commission has brought its first suit alleging anticompetitive conduct in connection with the prosecution and settlement of pharmaceutical patent litigation since the Supreme Court’s June 2013 decision in FTC v. Actavis. Although two commissioners dissented from the decision to (...)
19 avenue Jean Aicard
75011 Paris, France
106 West 32nd Street, Suite 144
New York, NY, 10001, USA
563 Chiswick High Road
W4 3AY London, UK
